Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development

Journal of Experimental Medicine

Volumn 204, Issue 5, 2007, Pages 1037-1047

  Aspord, Caroline ^a   Pedroza Gonzalez, Alexander ^a   Gallegos, Mike ^a   Tindle, Sasha ^a   Burton, Elizabeth C ^b   Su, Dan ^b   Marches, Florentina ^a   Banchereau, Jacques ^a   Palucka, A Karolina ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE SECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-13; INTERLEUKIN-4; MICE; MICE, INBRED NOD; MICE, SCID; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR;

EID: 34249000341     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061120     Document Type: Article

References (48)

1. Joyce, J.A. 2005. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 7:513-520.
2. Coussens, L.M., and Z. Werb. 2002. Inflammation and cancer. Nature. 420:860-867.
3. Steinman, R.M., D. Hawiger, and M.C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711.
4. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
5. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
6. Shortman, K., and Y.J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151-161.
7. Albert, M.L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:86-89.
8. Albert, M.L., S.F. Pearce, L.M. Francisco, B. Sauter, P. Roy, R.L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36 and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359-1368.
9. Heath, W.R., and F.R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:47-64.
10. Finkelman, F.D., A. Lees, R. Birnbaum, W.C. Gause, and S.C. Morris. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406-1414.
11. Banchereau, J., and A.K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
12. Gabrilovich, D. 2004. Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat. Rev. Immunol. 4:941-952.
13. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
14. Gabrilovich, D.I., H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, and D.P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-1103.
15. Chomarat, P., J. Banchereau, J. Davoust, and A.K. Palucka. 2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1:510-514.
16. Delamarre, L., M. Pack, H. Chang, I. Mellman, and E.S. Trombetta. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 307:1630-1634.
17. Enk, A.H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer. 73:309-316.
18. + regulatory T cell proliferation. J. Exp. Med. 202:919-929.
19. Levings, M.K., S. Gregori, E. Tresoldi, S. Cazzaniga, C. Bonini, and M.G. Roncarolo. 2005. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 105:1162-1169.
20. Terabe, M., and J.A. Berzofsky. 2004. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16:157-162.
21. Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190:1417-1426.
22. Thomas, R., K.P. MacDonald, A.R. Pettit, L.L. Cavanagh, J. Padmanabha, and S. Zehntner. 1999. Dendritic cells and the pathogenesis of rheumatoid arthritis. J. Leukoc. Biol. 66:286-292.
23. Radstake, T.R., A.W. van Lieshout, P.L. van Riel, W.B. van den Berg, and G.J. Adema. 2005. Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann. Rheum. Dis. 64:1532-1538.
24. Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953-964.
25. Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:1540-1543.
26. Banchereau, J., V. Pascual, and A.K. Palucka. 2004. Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 20:539-550.
27. Palucka, A.K., J. Gatlin, J.P. Blanck, M.W. Melkus, S. Clayton, H. Ueno, E.T. Kraus, P. Cravens, L. Bennett, A. Padgett-Thomas, et al. 2003. Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood. 102:3302-3310.
28. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
29. Nagata, K., K. Tanaka, K. Ogawa, K. Kemmotsu, T. Imai, O. Yoshie, H. Abe, K. Tada, M. Nakamura, K. Sugamura, and S. Takano. 1999. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol. 162:1278-1286.
30. Cosmi, L., F. Annunziato, M.I.G. Galli, R.M.E. Maggi, K. Nagata, and S. Romagnani. 2000. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30:2972-2979.
31. Wurster, A.L., T. Tanaka, and M.J. Grusby. 2000. The biology of Stat4 and Stat6. Oncogene. 19:2577-2584.
32. Skinnider, B.F., A.J. Elia, R.D. Gascoyne, B. Patterson, L. Trumper, U. Kapp, and T.W. Mak. 2002. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 99:618-626.
33. Ansel, K.M., I. Djuretic, B. Tanasa, and A. Rao. 2006. Regulation of Th2 differentiation and Il4 locus accessibility. Annu. Rev. Immunol. 24:607-656.
34. Kapp, U., W.C. Yeh, B. Patterson, A.J. Elia, D. Kagi, A. Ho, A. Hessel, M. Tipsword, A. Williams, C. Mirtsos, et al. 1999. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189:1939-1946.
35. Skinnider, B.F., A.J. Elia, R.D. Gascoyne, L.H. Trumper, F. von Bonin, U. Kapp, B. Patterson, B.E. Snow, and T.W. Mak. 2001. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 97:250-255.
36. Trieu, Y., X.Y. Wen, B.F. Skinnider, M.R. Bray, Z. Li, J.O. Claudio, E. Masih-Khan, Y.X. Zhu, S. Trudel, J.A. McCart, et al. 2004. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res. 64:3271-3275.
37. Blais, Y., S. Gingras, D.E. Haagensen, F. Labrie, and J. Simard. 1996. Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol. 121:11-18.
38. Serve, H., E. Oelmann, A. Herweg, D. Oberberg, S. Serve, B. Reufi, C. Mucke, A. Minty, E. Thiel, and W.E. Berdel. 1996. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res. 56:3583-3588.
39. Minn, A.J., G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald, and J. Massague. 2005. Genes that mediate breast cancer metastasis to lung. Nature. 436:518-524.
40. Sinha, P., V.K. Clements, and S. Ostrand-Rosenberg. 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65:11743-11751.
41. Mantovani, A., A. Sica, and M. Locati. 2005. Macrophage polarization comes of age. Immunity. 23:344-346.
42. Munn, D.H., and A.L. Mellor. 2004. IDO and tolerance to tumors. Trends Mol. Med. 10:15-18.
43. Terabe, M., S. Matsui, J.M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
44. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
45. Park, J.M., M. Terabe, L.T. van den Broeke, D.D. Donaldson, and J.A. Berzofsky. 2005. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int. J. Cancer. 114:80-87.
46. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D.I. Godfrey, S. Ostrand-Rosenberg, M.J. Smyth, and J.A. Berzofsky. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202:1627-1633.
47. Sundrud, M.S., S.M. Grill, D. Ni, K. Nagata, S.S. Alkan, A. Subramaniam, and D. Unutmaz. 2003. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J. Immunol. 171:3542-3549.
48. Messi, M., I. Giacchetto, K. Nagata, A. Lanzavecchia, G. Natoli, and F. Sallusto. 2003. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat. Immunol. 4:78-86.